Figure 2.
Probability of sustained TFR relative to halving time, 3-month BCR-ABL1 value and fold-reduction. (A) Kaplan-Meier analysis of probability of remaining off TKI in all TFR attempts with 95% confidence intervals shown. (B) Logistic regression analysis demonstrating the probability of sustained TFR based on individual halving times demonstrating that the likelihood of TFR is reduced with longer halving times. (C) Kaplan-Meier analysis of sustained TFR based on the BCR-ABL1 halving time quartiles. (D) Kaplan-Meier analysis of sustained TFR based on the fold-reduction of BCR-ABL1 from baseline. Patients were divided into quartile values. (E) Kaplan-Meier analysis of sustained TFR based on the 3-month BCR-ABL1 value. Comparison of BCR-ABL1IS ≤ 0.1% vs other groups shown. (F) Kaplan-Meier analysis of sustained TFR based on whether patients achieved a BCR-ABL1IS ≤0.1% at 3 months.

Probability of sustained TFR relative to halving time, 3-month BCR-ABL1 value and fold-reduction. (A) Kaplan-Meier analysis of probability of remaining off TKI in all TFR attempts with 95% confidence intervals shown. (B) Logistic regression analysis demonstrating the probability of sustained TFR based on individual halving times demonstrating that the likelihood of TFR is reduced with longer halving times. (C) Kaplan-Meier analysis of sustained TFR based on the BCR-ABL1 halving time quartiles. (D) Kaplan-Meier analysis of sustained TFR based on the fold-reduction of BCR-ABL1 from baseline. Patients were divided into quartile values. (E) Kaplan-Meier analysis of sustained TFR based on the 3-month BCR-ABL1 value. Comparison of BCR-ABL1IS ≤ 0.1% vs other groups shown. (F) Kaplan-Meier analysis of sustained TFR based on whether patients achieved a BCR-ABL1IS ≤0.1% at 3 months.

Close Modal

or Create an Account

Close Modal
Close Modal